Elanco Animal Health (NYSE:ELAN) Earns Buy Rating from Analysts at UBS Group

UBS Group began coverage on shares of Elanco Animal Health (NYSE:ELAN - Free Report) in a research note published on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $18.00 price target on the stock.

Other analysts have also recently issued research reports about the stock. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 target price on the stock. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Barclays lifted their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. Morgan Stanley cut Elanco Animal Health from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Stifel Nicolaus reissued a "buy" rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $16.75.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded up $0.38 during midday trading on Monday, reaching $12.88. 4,181,769 shares of the company traded hands, compared to its average volume of 4,770,076. The firm's fifty day moving average price is $13.43 and its two-hundred day moving average price is $14.46. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 12 month low of $11.40 and a 12 month high of $18.80. The firm has a market capitalization of $6.37 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the business posted $0.18 EPS. The business's quarterly revenue was down 3.6% on a year-over-year basis. On average, equities analysts expect that Elanco Animal Health will post 0.92 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in ELAN. Commerce Bank lifted its position in shares of Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after purchasing an additional 741 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of Elanco Animal Health by 3.6% during the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company's stock worth $352,000 after buying an additional 893 shares during the last quarter. HBK Sorce Advisory LLC boosted its stake in shares of Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company's stock valued at $186,000 after acquiring an additional 1,107 shares during the last quarter. Atomi Financial Group Inc. grew its position in shares of Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company's stock valued at $177,000 after purchasing an additional 1,221 shares during the period. Finally, Keene & Associates Inc. raised its position in shares of Elanco Animal Health by 5.7% in the 3rd quarter. Keene & Associates Inc. now owns 22,945 shares of the company's stock worth $337,000 after buying an additional 1,240 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.